A Study of ES014 in Subjects With Advanced Solid Tumors

Inclusion Criteria: * Histological or cytological documentation of unresectable locally advanced or metastatic solid tumours. * Presence of at least one measurable lesion (according to RECIST v1.1). * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1. * Life expectancy of at least 12 weeks. * Adequate hematologic, hepatic, renal and coagulation functions per protocol. Exclusion Criteria: * Any prior therapy targeting CD39, CD73, adenosine A2A receptor, or TGF-β. * Receipt of any investigational agents or devices within 4 weeks prior to the first dose of study drug. * Prior treatment with the following therapies: Anticancer therapy within 28 days or 5 half-lives of the drug prior to the first dose of study drug, whichever is shorter. At least 14 days must have elapsed between the last dose of prior anticancer agent and the first dose of study drug is administered with certain exceptions. A wash out of at least 2 weeks before the start of study drug for radiation to the extremities and 4 weeks for radiation to the chest, brain, or visceral organs is required. * Prior allogeneic or autologous bone marrow transplant or solid organ transplant. * Subject has received an infusion of blood products (including platelets or red blood cells), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant erythropoietin, or recombinant thrombopoietin within 14 days prior to the first administration of study treatment.